Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015

チロシンキナーゼ阻害剤の世界市場及びパイプラインインサイト

◆タイトル:Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
◆商品コード:KUICK504092
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年4月
◆ページ数:1200
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,400 ⇒換算¥271,200見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD4,800 ⇒換算¥542,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、チロシンキナーゼ阻害剤の世界市場について調査・分析し、チロシンキナーゼ阻害剤治療の仕組み、チロシンキナーゼ阻害剤の世界市場概要、市場の動態、市場展望、チロシンキナーゼ阻害剤のパイプライン動向、上市品分析、競争状況、主要企業分析等の情報をお届けいたします。

Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for phosphorylation.It has been found that mutation or other anomaly in these enzymes causes uncontrolled cell division leading to cancer. Because of their direct involvement in cell division they are used in cancer treatment by using kinase inhibitors to prevent unregulated cellular proliferation. Epidermal Growth Factor Receptor Family (EFGR) are present on the cell surface and anomalies like mutations leads to the cancer formation and its members have been found to have activity like receptor tyrosine kinases. EFGR Members of these families have been found to be overexpressed in various malignancies like breast cancer, glioblastoma and lung cancer. They are utilized for formulating targeted therapeutics for cancer treatment. Her1/ Her2 are commonly found to be overexpressed in case of breast cancer and many cancer therapeutics have been developed to treat metastatic condition.

Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at various phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. As a result, several products are at different stages of clinical trials which will be introduced in market in coming years. Some tyrosine kinase medical care products including mAbs are costly to produce but large patient base and superior pharmacological benefits are some factors responsible for continuous growth of this market segment. Development and discovery of innovative technologies for commercialization is increasing because of large financial inputs. As a result, more therapeutic options will be available to patients at cost effective rates. Their disease coverage is increasing continuously due to which their market penetration is expected to increase several folds in coming years.

Increasing disease incidences especially cancer has attracted several pharmaceutical companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first of this kind to enter in global market. Targeted therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine kinase inhibitors are expected to increase in coming years. Small molecule based targeted therapeutics will offer competition to monoclonal antibodies in terms of pharmacological efficacy but pricing and commercialization strategies are also expected to play a major role.

Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy profiles along with minimized side effects. Several mAbs biding to different tyrosine receptors have been formulated by pharmaceutical companies generating significant revenues across the globe. For instance, Genentech’s trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor kinase due to which severe competition would be found in certain categories. EFGR is widely studied due to which majority of tyrosine kinase therapeutics belong to this category. Moreover, it is involved in breast cancer which has well developed market so revenues generated by this segment are expected to be significantly higher than other cancer categories.

Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive product are expected to enter continuously in global market. Owing to increasing disease incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic.

” Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015″ Report Highlight:
• Global Tyrosine Kinase Therapeutics Market Overview
• Mechanism of Tyrosine Kinase Therapeutics
• Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase
• Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs
• Majority Drugs in Preclinical Phase: 239 Drugs
• Marketed Tyrosine Kinase Inhibitors: 58 Drugs
• Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication

【レポートの目次】

1. Introduction to Tyrosine Kinases Inhibitors

2. Mechanism of Tyrosine Kinase Therapeutics

3. Global Tyrosine Kinase Therapeutics Market Overview
3.1 Current Market Scenario
3.2 Tyrosine Kinase Inhibitors Pipeline Overview

4. Global Tyrosine Kinase Therapeutics Market Dynamics
4.1 Favorable Market Parameters
4.2 Market Challenges

5. Global Tyrosine Kinase Therapeutics Market Future Prospects

6. Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered

7. Marketed Tyrosine Kinase Inhibitors by Company & Indication

8. Suspended & No Development Reported Tyrosine Kinase Inhibitors Pipeline
8.1 No Development Reported
8.2 Discontinued
8.3 Market Withdrawal
8.4 Suspended

9. Competitive Landscape
9.1 Advenchen Laboratories
9.2 Array Pharmaceuticals
9.3 AstraZeneca
9.4 Bayer Healthcare Pharmaceuticals
9.5 Biogen Idec
9.6 Bristol-Myer Squibb
9.7 Boehringer Ingelheim
9.8 Chugai Pharmaceutical
9.9 Celgene Corporation
9.10 Exelixis
9.11 Incyte Corporation
9.12 GalaxoSmithKline
9.13 Johnson & Johnson
9.14 Merck
9.15 Novartis
9.16 Onyx pharmaceuticals
9.17 Pfizer
9.18 Sanofi
9.19 Tolero Pharmaceutical
9.20 QIAGEN

Figure 1-1: Flow Chart of Phosphorylation
Figure 1-2: Hierarchy of EFGR Family
Figure 1-3: Hierarchy of VEGFR Family
Figure 1-4: Features of Receptor Tyrosine Kinase
Figure 1-5: Benefits of Tyrosine Kinase Inhibitors
Figure 2-1: Properties of Tyrosine Kinase Therapeutics
Figure 2-2: Mechanism of Nexavar
Figure 2-3: Mechanism of Gleevac
Figure 2-4: Mechanism of Tyverb
Figure 2-5: Benefits of Monoclonal Antibodies
Figure 2-6: Mechanism of Avastin
Figure 2-7: Mechanism of Rituximab
Figure 3-1: Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 3-2: Tyrosine Kinase Inhibitors Pipeline by Phase (Numbers), 2015
Figure 3-3: No Development Reported in Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 3-4: No Development Reported in Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
Figure 3-5: Discontinued Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 3-6: Discontinued Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
Figure 3-7: Suspended Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 3-8: Suspended Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
Figure 4-1: Tyrosine Kinase Therapeutics Favorable Market Parameters


【掲載企業】

Advenchen Laboratories, Array Pharmaceuticals, AstraZeneca, Bayer Healthcare Pharmaceuticals , Biogen Idec, Bristol-Myer Squibb,Boehringer Ingelheim, Chugai Pharmaceutical, Celgene Corporation, Exelixis, Incyte Corporation, GalaxoSmithKline, Johnson & Johnson, Merck, Novartis, Onyx pharmaceuticals, Pfizer, Sanofi, Tolero Pharmaceutical, QIAGEN


【レポートのキーワード】

チロシンキナーゼ阻害剤、治療、薬剤、パイプライン

★調査レポート[チロシンキナーゼ阻害剤の世界市場及びパイプラインインサイト] ( Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015 / KUICK504092) 販売に関する免責事項
[チロシンキナーゼ阻害剤の世界市場及びパイプラインインサイト] ( Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015 / KUICK504092) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆